![](https://tracker.live.rns-distribution.com/track.live-rns/5278260_d9353a075fe0b610698e373da828b7e4.png)
24 July 2024
TruSpine Technologies plc
("TruSpine" or the "Company")
Convertible Loan Note Extension & Related Party Transaction
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, that further to the announcement on 28 March 2024, the Company has extended the maturity date of the convertible loan note ("CLN") to 30 June 2025. All other terms of the CLN remain unchanged.
Related Party Transaction
The extension of maturity date of the CLN (the "Transaction") is a related party transaction for the purposes of Rule 4.6 of the AQSE Growth Market Access Rulebook, by virtue of the Company and Geoff Miller, Non-executive Chairman of the Company, being a party to the CLN. The directors of TruSpine independent of the Transaction confirm that, having exercised reasonable care, skill and diligence, the Transaction is fair and reasonable insofar as the shareholders of TruSpine are concerned.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
-END-
TruSpine Investor Hub | |
TruSpine Technologies Plc | Tel: +44 (0)20 7118 0852 |
Geoff Miller, Non-executive Chairman | |
| |
Cairn Financial Advisers LLP (AQSE Corporate Adviser) | Tel: +44 (0)20 7213 0880 |
Liam Murray / Ludovico Lazzaretti | |
Peterhouse Capital Limited (Broker & Financial Adviser) | |
Lucy Williams / Duncan Vasey
| |
Novus Communications (PR and IR) | Tel: +44 (0)1273 704 473 |
Alan Green / Jacqueline Briscoe |
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.